Human evidence that changed what happened next.

Genetic validation supported a $600M in-licensing decision at Board of Directors' level. The asset succeeded in Phase 2.

5Prime provided human causal evidence for a target-indication pair under consideration for a major acquisition or licensing deal. The evidence supported the decision. Phase 2 succeeded.

5Prime validated a causal target and biomarker for a common disease. We showed that a non-human safety signal would likely not translate to humans. Phase 2 was successful—as predicted.

A biotech partner needed human genetic validation to unlock investor capital. 5Prime validated the causal gene and a proximal biomarker. The evidence was clear and decision-ready. The company executed a successful Phase 2a, with primary outcome, side-effect and biomarker results, as predicted by 5Prime.

Evidence showed that the target's biomarker was a consequence of disease, not a cause. A >$100M trial was stopped before it started.

5Prime revealed reverse causation: the disease was causing the biomarker elevation, not the other way around. The target was not causal. The program was stopped, protecting the organization from a trial that would have failed to show efficacy by design.